Novartis spent most of the past year telling investors that 2026 would be a tale of two halves, with the generic erosion of Entresto and other older brands front-loaded and growth reappearing later in the year. The second quarter delivered the turn, as sales grew again in constant currency. The third-quarter report, due before the open on October 27, is where that recovery has to show it can hold up without help from the calendar.

The Street is looking for earnings of $2.25 a share on revenue of about $14.56 billion. That works out to roughly 4.7% sales growth and earnings flat with the year-ago quarter. The gap between those two numbers is the story. Management flagged that the second quarter was flattered by about a point of sales and roughly five points of core operating income from one-time phasing, tied to inventory around an SAP system cutover and to the timing of R&D spending. Both are expected to reverse in the back half. Add continued dilution from the Avidity acquisition, which helped push second-quarter core margin down 70 basis points to 41.2%, and analysts are effectively modeling a quarter where the top line improves but profits stand still. Full-year guidance was reaffirmed rather than raised last quarter. A clean quarter would show that the reversal is landing as management described, not worse.

The revenue side carries the burden of proof. Growth drivers accelerated to 36% in constant currency in the second quarter, and the brand details matter here. Scemblix grew 89% and management is aiming for leadership in US first-line new prescriptions during the second half, so any evidence on that front will test whether the leukemia drug is becoming a true franchise. Kisqali passed $1 billion in quarterly US sales for the first time, but its growth slowed to 43% from 55%. Investors will want to know whether that slowdown is just the math of a bigger base or the start of a flatter curve. Leqvio and Kesimpta, growing 59% and 32% respectively, need to keep compounding to offset the larger generic hole left by Entresto, Promacta and Tasigna.

There are also fresh soft spots to monitor. Cosentyx is facing tougher competition in China, and court rulings have cleared a path for rival versions of Lutathera. Neither threatens the overall thesis by itself, but a visible drag from either would chip away at the idea that the growth engines can fully absorb the patent cliff. On the positive side, an approval of Pluvicto in earlier-stage hormone-sensitive prostate cancer, expected in the third quarter, would expand its eligible patient pool by about 75%. The quarter also falls in the middle of a dense readout calendar, including pelacarsen, remibrutinib in multiple sclerosis and hidradenitis suppurativa, del-desiran in myotonic dystrophy and ianalumab. Management has framed these readouts as possible reasons to lift its mid- to long-term growth outlook.

The market has not been in a generous mood. Shares have slipped 3.1% since the last report while the S&P 500 gained 2.3%, and bullish sentiment has collapsed from about 19.7% before the prior quarter to essentially neutral. At $150.62, the stock sits just under its 200-day moving average and roughly midway in its post-earnings range of $137 to $164.48. That positioning suggests skepticism about margins rather than about the pipeline, and it leaves the bar modest.

The central question is whether Novartis can show that sales momentum outruns the expected reversal of second-quarter timing benefits and Avidity dilution. If the growth brands keep accelerating and margins hold close to plan, the second-half recovery narrative stays intact and the pipeline gets room to drive the next leg. If profits dip below the flat bar, the year of recovery starts to look more like a year of waiting.